Companies › Ashvattha Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Other, Neurology, Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Aflibercept (D-4517) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
| 18F-OP-801 Biomarker for PET imaging of activated microglia and macrophages | – | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | – |
| MGB (Migaldendranib) | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05387837 | Aflibercept (D-4517) | Phase 2 | Neovascular Age-related Macular Degeneration | Ophthalmology | May 2025 |
| NCT05395624 | 18F-OP-801 | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | Neurology | Jan 2026 |
| NCT07370155 | MGB (Migaldendranib) | Phase 1 | Healthy Volunteers | Other | Mar 2026 |
EnnovaBio Design Therapeutics Samsung Bioepis Centessa Pharmaceuticals (UK) H. Lundbeck
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.